Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
May 1st, 2007
Introgen Therapeutics, Inc. (NASDAQ:INGN) reported updated ADVEXIN(R) biomarker data over the weekend in Los Angeles, California at the Annual Meeting of the American Association for Cancer Research. Abnormality of the p53 tumor suppressor is one of the most common and fundamental molecular defects in cancer. ADVEXIN's mechanism of action is targeted to restoring p53 tumor suppressor function and the detection of abnormal p53 is a logical predictive biomarker for ADVEXIN efficacy. In a study of 28 recurrent head and neck cancer patients in Phase 2 clinical trials, abnormal p53 was shown to correlate with increased survival and tumor responses following ADVEXIN...
Source: Cancer Weekly (2007-05-01)
|
